BioPharmSignal logoBioPharmSignal

Biotech News

IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development

IN8bio (INAB)IN8bioCompany update

Renowned γδ T cell and T cell engager (TCE) expert brings two decades of drug discovery and development experience to IN8bio Appointment strengthens IN8bio’s leadership and domain expertise as they advance their novel γδ T cell engager platform NEW YORK, Sept.

Related news

INABIN8bio2026-10-06 20:00 EST

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

INABIN8bio2026-09-22 20:00 EST

IN8bio to Present at Sidoti Small-Cap Virtual Conference

STROSutro Biopharma2026-09-29 12:00 EST

Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development

IDYAIDEAYA Biosciences2026-09-28 10:00 EST

IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development

NRIXNurix Therapeutics2026-10-05 11:00 EST

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

KURAKura Oncology2026-09-08 11:00 EST

Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer

View all latest news

IN8bio

Gamma-Delta T-Cell Therapies IN8bio develops gamma-delta T-cell therapies and T-cell engagers for cancer and autoimmune disease. The platform seeks to use the innate and adaptive properties of gamma-delta T cells to recognize stressed or malignant cells. Glioblastoma Program The company's clinical work in glioblastoma evaluates...

Recent company news

INABIN8bio2026-10-06 20:00 EST

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

INABIN8bio2026-09-22 20:00 EST

IN8bio to Present at Sidoti Small-Cap Virtual Conference

INABIN8bio2026-09-10 12:00 EST

IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference

INABIN8bio2026-09-09 12:00 EST

IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development

INABIN8bio2026-08-10 20:01 EST

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
1.39 USD
Market cap
14.96M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States